Journavx revenue surged as Vertex Pharmaceuticals reported $3.33 billion Q2 earnings, driven by the new acute pain drug’s strong sales and a…
Sparsentan FSGS treatment offers a new FDA‑approved option for focal segmental glomerulosclerosis, prompting clinicians to compare it with…
Journavx revenue surged as Vertex Pharmaceuticals reported $3.33 billion Q2 earnings, driven by the new acute pain drug’s…
Discover how ALK-positive lung cancer treatment is evolving with new inhibitors, improving survival for thousands of patients worldwide.
Biosimilars reduce drug costs by up to 70%, but patient access depends on insurance coverage and policy decisions.
Discover how obesity medications like semaglutide may help manage metabolic side effects from antipsychotics.
Learn why user access to Yesafili, a biosimilar for eye conditions like wAMD, may be restricted and how…
Zambia's delay in signing a health memorandum with the US stems from disagreements over data and specimen sharing,…
Lenacapavir for HIV PrEP accounted for only 1% of all PrEP in the first six months after FDA…
Learn why user access was denied after restriction policies changed, impacting employees like Ashley Holzworth-Nash at Express Scripts.
Users report website access blocks that are preventing login and restricting access to vital online services and digital…
